Unsafe: NME Withdrawals After Postmarket Safety Issues
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
New molecular entities that were withdrawn from the U.S. market, either voluntarily or at FDA’s request, in the wake of safety concerns that emerged post-marketing. Iclusig brings the count to 23, but the cancer drug could return under conditions of restricted use.